Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Current Deferred Revenue (2017 - 2025)

Acro Biomedical (ACBM) has 9 years of Current Deferred Revenue data on record, last reported at $20000.0 in Q4 2025.

  • For Q4 2025, Current Deferred Revenue changed 0.0% year-over-year to $20000.0; the TTM value through Dec 2025 reached $20000.0, changed 0.0%, while the annual FY2025 figure was $20000.0, 0.0% changed from the prior year.
  • Current Deferred Revenue reached $20000.0 in Q4 2025 per ACBM's latest filing, roughly flat from $20000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $20000.0 in Q1 2021 and bottomed at $20000.0 in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $20000.0, with a median of $20000.0 recorded in 2021.
  • The widest YoY moves for Current Deferred Revenue: up 0.0% in 2021, down 0.0% in 2021.
  • A 5-year view of Current Deferred Revenue shows it stood at $20000.0 in 2021, then changed by 0.0% to $20000.0 in 2022, then changed by 0.0% to $20000.0 in 2023, then changed by 0.0% to $20000.0 in 2024, then changed by 0.0% to $20000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $20000.0 in Q4 2025, $20000.0 in Q3 2025, and $20000.0 in Q2 2025.